Jason O’Byrne, MBA

Executive Vice President and Chief Financial Officer

Jason O’Byrne, MBA, serves as Executive Vice President and Chief Financial Officer (CFO). Mr. O’Byrne leads the Finance, Investor Relations, Operations and IT organizations at Vir Biotechnology. He has spent over 20 years in finance and operations with demonstrated effective financial leadership in capital allocation and formation, corporate strategy and operational execution.

Prior to joining Vir Biotechnology in October 2024, Mr. O’Byrne served as CFO at Caribou Biosciences, where he managed the Finance, Investor Relations, Corporate Communications, IT and the Operations organizations. He also led multiple capital formation initiatives at Caribou, including the IPO in 2021 and a follow-on offering in 2023. Previously, Mr. O’Byrne served as Senior Vice President of Finance at Audentes Therapeutics, where he oversaw the financial due diligence and integration related to the company’s $3 billion acquisition by Astellas Pharma in 2020. Earlier in his career, Mr. O’Byrne spent 13 years with Genentech and its parent company Roche, holding finance leadership and executive positions of increasing responsibility and geographical reach and building broad operational finance expertise across manufacturing, research, clinical development, business development and commercial functions. During his Genentech/Roche tenure, he served as Vice President, Head of Finance for Roche Asia-Pacific and Vice President, Global Head of Finance for Product Development and Product Strategy.

Mr. O’Byrne holds an MBA in Finance, with distinction, from New York University’s Stern School of Business and a Bachelor of Applied Science in Mechanical Engineering from the University of British Columbia.